INTRODUCTION
Melanocytes produce melanin pigment in mammals and reside in the skin, eye, ear, meninges and Harderian gland. Melanin is synthesised by sequential oxidation and hydroxylation of tyrosine and is stored in the cytoplasm in membrane-bound melanosomes (Ito, 2003) . These organelles share some characteristics with lysosomes eg. acidic pH and the presence of some lysosomal resident proteins but also have distinct components such as tyrosinase, TRP-1 and TRP-2 that are involved in melanogenesis (Marks and Seabra, 2001 ).
Skin melanocytes reside in the basal layer of the epidermis and hair bulbs where their highly dendritic morphology allows them to contact and transfer pigment into many dividing keratinocytes.
Mouse and human genetic studies have identified a number of gene products involved in normal pigmentation (Bennett and Lamoreux, 2003) . Many of these products are believed to contribute to the specialised membrane trafficking events required for melanogenesis and a subset have been identified that appear to affect the intracellular melanosome distribution and intercellular transport instead of biogenesis. These mouse mutants and patients are thought to suffer albinism as a result of the fact that pigment accumulates around the melanocyte nucleus and transfers in an abnormal manner from melanocyte dendrites to keratinocytes (Marks and Seabra, 2001) . Seminal video microscopic studies of melanosome movements in melanocytes from one such mutant (dilute) that is defective in the molecular motor, MyoVa indicated that melanosomes undertake microtubule-based transport to the dendrite tips and then are retained there by MyoVa-mediated interaction with the cortical actin cytoskeleton (Wu et al., 1998) . Functional loss of Rab27a, as in ashen mice and Griscelli Syndrome 2 (GS2), or Mlph (also known as Slac2-a), as in leaden mice and GS3, result in similar defects in intracellular transport of mature melanosomes implicating these three gene products in the same pathway. We and others have established that active GTP-bound Rab27a associates with melanosomes resulting in the sequential recruitment of the modular adaptor protein Mlph and the actin-dependent motor MyoVa resulting in coupling of melanosomes to the cortical actin cytoskeleton Nagashima et al., 2002; Strom et al., 2002; Wu et al., 2002a) .
Mlph is one of a growing family of Rab27a 'effector' proteins, i.e. proteins that preferentially bind the activated GTP-bound form of Rab27a (Fukuda, 2005) . There is some evidence that cell type-specific expression of this diverse effector family allows Rab27a to fulfil different functions in the different cell types in which it is expressed . With the exception of Munc13-4, all these proteins contain an N-terminal 150 aa Rab27-binding domain (R27BD) comprising two SHD domains which may be adjacent or separated by a putative Zn 2+ finger motif (ZnF). In Slp1/JFC1, Slp2-a, Slp3-a, Slp4-a/granuphilin-a, Slp5 and Rabphilin, the R27BD is followed by tandem C2 domains, which mediate phospholipid binding and there is evidence that these proteins, together with Noc2
and Munc13-4, regulate fusion of secretory granules with the plasma membrane in several cell types (Fukuda, 2005) .
In contrast, Mlph/Slac2-a and MyRIP/Slac2-c have similar medial and C-terminal sequences that lack tandem C2 domains and play a role in binding members of the myosin family of molecular motors, MyoVa and MyoVa/VIIa respectively, and actin . Consequently, these proteins are both thought to play a role in organelle movement rather than secretion. A number of recent studies have investigated the role of the C-terminus of Mlph in melanosome transport and its role in binding MyoVa, actin and EB1
( Figure 1 ). Our lab and others found the medial region of Mlph to be necessary and sufficient for binding of the C-terminal tail domain of MyoVa (aa 1258-1853 in mouse) (Nagashima et al., 2002; Strom et al., 2002) . Moreover, the melanocyte-specific exon F appears to be absolutely required for MyoVa to interact with Mlph (Wu et al., 2002a) . More recently it has been proposed that a second domain of interaction between the globular tail of MyoVa and a more N-terminal region (aa 147-240 of mouse sequence) Mlph may exist Kuroda, 2002, , 2004) . It has also been suggested that the C-terminus of Mlph (mouse aa 400-590) may directly interact with actin, and that this is important in allowing proper melanosome distribution to the dendrite tips (Kuroda et al., 2003) . Finally, the C-terminus of Mlph (aa 490-590 in mouse) has been implicated in binding EB1. This interaction might allow it to track to the peripheral dendrite tips on the plus-end tips of growing microtubules where it would reside in complex with actin-associated MyoVa until a suitable Rab27a-associated melanosome could be captured (Wu et al., 2005) .
The primary objective of the present study was to examine the contribution of the individual domains of Mlph to its overall function. To achieve this end, we have established a novel cell culture melanosome transport assay that measures the extent of recovery of melanosome transport defects in leaden (ln) melanocytes, that result from over-expression of Mlph and mutants that specifically lack individual domains. This cell culture melanosome transport assay allowed us to examine questions arising from the genetic and biochemical data in a cellular context.
MATERIALS AND METHODS

Plasmids
Preparation of pEGFPC2-Mlph was described previously . Plasmids pCS26xMyc-Mlph SHD1, pCS-26xMyc-MlphSHD1+ ZnF, pCS-26xMyc-MlphSHD1+ ZnF +SHD2, pCS-26xMyc-Mlph ZnF +SHD2, pCS-26xMyc-MlphSHD2, pCS-26xMyc-MlphSHD1+SHD2, pCS-26xMyc-Mlph For production of pGEX-4T1-Mlph constructs, that allow the synthesis of fragments of Mlph fused at the C-terminus of GST, the appropriate regions of Mlph coding sequence were amplified by PCR using IMAGE clone 4862487 as template. PCR products were digested with restriction enzymes EcoR1 and Xho1 and ligated into empty pGEX-4T1 prepared using the same enzymes. A pGEX-4T1 clone encoding GST-Mlph150-500AP was produced in the same way using pCS26xMyc-Mlph A467P as template. pMAL-c2XMyoVa MSGTA encoding MyoVa MS-GTA (aa1260-1853 and including alternatively spliced exons D and F and lacking exon B) fused to the C terminus of E.coli maltose binding protein MBP was produced by subcloning of MyoVaMSGTA from pLEX MyoVaMSGTA using EcoR1 and Sal1 restriction endonucleases into pMAL-c2X (New England Biolabs) prepared using the same enzymes. The fidelity of sequences of clones was confirmed by DNA sequencing. All oligonucleotide primers were synthesized and desalted by SigmaGenosys (Cambridge, UK) and alignment of protein sequences was using ClustalW available at http://pbil.univ-lyon1.fr/. The sequence of all oligonucleotide primers using in this study are available of request.
Generation and maintenance of immortal melan-ln melanocytes
To facilitate the generation of immortal melanocytes, C57BL/6J-ln fz H54/+ + H54, mice homozygous for ln were crossed with C57BL6/J mice carrying an Ink4a-Arf exon 2 deletion (Serrano et al., 1996) . These crosses were performed at Texas A&M University by Lynn
Lamoreux. Four individual trunk skins of neonatal F2 ln/ln mice were used at St George's, University of London for preparation of melanocyte cultures, as described previously (Sviderskaya et al., 2002) , yielding immortal lines melan-ln1, 2, 3 and 4. These were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine,100 U/ml penicillin G and 100 mg/ml (all from Invitrogen Paisley, UK), 200 nM phorbol 12-myristate 13-acetate, 200 pM cholera toxin (both from Sigma-Aldrich, Poole, UK), at 37°C with 10% CO 2 . Melanocytes for transfection and microinjection were seeded onto glass coverslips at the appropriate density and grown overnight and used the following day. Data presented in this paper were obtained in experiment using the melan-ln3 cell line, however similar results were obtained when experiments were repeated in other melan-ln cell lines and primary cultures of melanocytes derived from ln/ln mice.
Transfection and microinjection of melanocytes
melan-ln melanocytes grown on 13mm diameter round cover-slips were transfected in Optimem serum free medium (Invitrogen) with plasmid DNA using Fugene6 transfection reagent (Roche, Lewes, UK) using a ratio of 0.5μg DNA:2μl of Fugene6. DNA:Fugene6 complexes were removed from cells after 3hrs and replaced with full medium. melan-ln3 melanocytes were micro-injected with pEGFPC2-Mlph (0.01mg/ml) using a microscope . Images were processed using Leica TCS-NT software associated with the microscope and Adobe Photoshop CS software.
All images presented are single sections in the z-plane. For quantitation of expression level and extent of rescue of melanosome transport cells fixed and stained on the same day were examined blind the following day and non-saturated 8-bit fluorescence and transmission images were obtained using identical laser power, PMT voltages and acousto-optical filter settings. Using these images the total area, the melanosome filled area and the average fluorescence intensity of cells was determined manually using NIH ImageJ software (http://rsb.inof.ni.gov/ij/). To determine the extent of rescue of melan-ln melanosome transport defects by introduced constructs, the rescue ratio was calculated by dividing the melanosome filled area by the total cell area. The statistical significance of results of the rescue assay for each experimental protein was determined by pair-wise comparison of rescue ratios with those achieved by positive (Mlph) and negative (Slp1) control proteins using student-t test (Table 1) .
Time-lapse microscopy
Living melan-ln3 melanocytes expressing EGFP-Mlph were maintained at 37 0 C in growth medium in a closed FCS2 perfusion chamber (Bioptechs) combined with an objective heater (Bioptechs) on the stage a Zeiss Axiovert 200 microscope. Observation was using a 40x
1.0NA oil-immersion objective lens and fluorescence and phase contrast images were gathered using a Hamamatsu ORCA-ER charged coupled device camera driven by OpenLab TM software (Improvision, Coventry UK). Movies were assembled using ImageJ software.
In vitro assay of interaction of purified MyoVa C-terminus tail and Mlph
MBP tagged MyoVaMSGTA and GST tagged Mlph proteins were expressed in BL21-codon plus (DE3)-RIPL strain and purified from bacterial lysate using affinity chromatography as outlined in the manufacturer's instructions (New England Biolabs and Amersham, respectively). 100 pmole GST-Mlph was mixed with 100 pmole MBP-MSGTA in buffer A (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl 2 , 1 mM DTT and 0.075 mM Nonidet P-40) and incubated for 30 mins at RT with gentle agitation. 20 μl equilibrated glutathione-sepharose beads were added to each reaction and incubated for 30 mins at RT with gentle agitation. The glutathione-sepharose beads were precipitated by centrifugation and washed twice with 1 ml buffer A. Bound proteins were eluted by boiling the beads in SDS loading buffer and the eluates were analysed by immunoblotting using antibodies specific for GST and MBP. Signals were analysed using a Fujifilm LAS3000 and quantified using Aida software.
Mlph adenovirus production, infection of melan-ln melanocytes and immunoprecipitation of over-expressed Mlph
We modified the BLOCK-iT RNAi adenoviral expression system (Invitrogen, Paisley, UK)
to produce replication incompetent adenoviruses that allow transient expression of Mlph proteins in melan-ln melanocytes. To allow insertion of Mlph coding sequence into the adenovirus packaging vector pAd/BLOCK-iT-DEST pENTR286 was constructed on the backbone of pENTR/U6 (Invitrogen) by swapping the U6 promoter and termination signal of PolIII with the expressing cassette as follows. First, a polylinker (with BglII, EcoRI, BsiwI, SpeI, NotI, SacII, KpnI, SacI, BamHI restriction sites) was inserted into pEGFPC2 vector (Clontech, Mountain View, CA, USA) by annealing the appropriate primers and ligating into XhoI/BamHI sites. The EGFP coding sequence was then removed from the modified pEGFP vector by restriction digest AgeI/BglII, over-hanging ends were filled-in using Klenow fragment and the vector was re-ligated. The expression cassette (CMV promoter/polylinker/sv40 poly adenylation signal) was amplified by PCR from the previously modified vector using Phusion DNA polymerase (New Enland Biolabs, England).
In order to metyhylate the internal XbaI site, the PCR product was cloned into pcDNA3.1/V5/His-TOPO vector (Invitrogen). The expression cassette was released from pcDNA3.1/V5/His using SalI/XbaI previous introduced by PCR and inserted into pENTR/U6 using the same restriction sites, resulting in a mammalian expression vector (pENTR286) with CMV promoter/polylinker/SV40 poly-adenylation signal flanked by attL1 and attL2
sequences. pENTR286 vectors encoding N-terminal V5-tagged Mlph1-266aa, Mlph1-400aa, Mlph1-490aa and Mlph1-590aa were prepared by PCR amplification of the appropriate fragments of Mlph using IMAGE clone 4862487 as template. Incorporation of the CMV promoter/Mlph/sv40 poly-adenylation signal cassette into the adenovirus packaging vector was performed using LR clonase II ( was then incubated with 2 μg of mouse anti-V5 and 50 μl of sheep anti-mouse Dynabeads (Dynal) overnight at 4ºC with end-over-end rotation. Immune complexes were then harvested using the Dynal magnetic particle collector, washed 3 times using buffer, subjected to SDS-PAGE and immunoblotted using rabbit antibodies specific for V5 and MyoVa as described below.
Immunoblotting
Cells were lysed by resuspension in buffer (20mM Tris pH 7.5, 100mM NaCl, 1mM
DTT, 0.1% CHAPS and protease inhibitor cocktail) followed by sonication. PNS was prepared by centrifugation at 1000g for 15 mins at 4ºC and resolved using 10% SDS-PAGE and transferred to PVDF membranes. Membranes were blocked in solution 2 (PBS, 0.2%
Tween-20, 5% non-fat dry milk), incubated with primary antibody diluted in solution 3 (PBS, 0.2% Tween-20) for 1h to overnight, washed with solution 3, followed by incubation for 30 min with 1:10,000 dilution of appropriate HRP-conjugated secondary antibody (Dako, High
Wycombe, Bucks., UK) diluted in solution 2 and washing as before. Bound antibody was detected using the ECL Substrates (Amersham, UK). Blots were calibrated with prestained molecular weight standards (Bio-Rad, Hemel Hempstead, Herts., UK). Conditions for 4B12 mouse anti-Rab27a and DB51 rabbit anti-MyoVa have been described previously while goat anti-Mlph (Everest Biotech, Oxford, UK) was used at 0.5μg/ml.
RESULTS
Immortal melan-ln cells appear indistinguishable from primary ln/ln melanocytes.
In order to establish a cell culture melanosome transport assay with which to examine the role of different domains of Mlph and its binding partners in melanosome transport in living melanocytes, we generated immortal ln/ln melanocyte cell lines derived from mice doubly homozygous for the ln and ink4A null alleles, as described previously for an ashen cell line (see details under "Materials and Methods") (Ali et al., 2004 . This is consistent with published observations that Mlph contains PEST sequences, is highly susceptible to degradation by cytosolic proteases and that high levels of over-expression of EGFP-Mlph in wild-type melanocytes disrupt peripheral tethering of melanosomes, suggesting that in vivo the expression level and rate of turnover of Mlph is tightly controlled (Fukuda and Itoh, 2004) .
Remarkably, in many instances full rescue of melanosome transport is observed in cells expressing levels of EGFP-Mlph that can only be detected using Mlph-specific antibodies to stain transfected cells (unpublished observations). Therefore, in further experiments we employed a Myc-tagged Mlph fusion protein comprising six consecutive copies of the Myc epitope fused to the N-terminus of murine Mlph as this allowed us to detect lower levels of over-expressed protein than could be observed using EGFP fluorescence as a marker of Mlph expression.
SHD1 and SHD2 are both required for recruitment of Mlph to melanosomal membranes.
We first examined the regions of Mlph responsible for its recruitment to melanosomal membranes to examine its requirements for interaction with activated Rab27a in the context of living melanocytes. Previous studies indicated that the N-terminal region of Mlph, aa 1-150 in mouse, that contains SHD1 and SHD2, conserved in many Rab27 effectors, and an intervening ZnF, is responsible for interaction with Rab27a and has been termed R27BD (Rab27a binding domain) (Fukuda, 2002; Strom et al., 2002; Wu et al., 2002a) .Within this region, SHD1 is proposed to be sufficient for interaction with GTP-bound Rab27a in vitro (Fukuda, 2002; Strom et al., 2002) . We introduced several constructs encoding these domains alone or in combination into melan-ln melanocytes and determined their intracellular localisation using confocal microscopy ( Figure 3 ). We observed that only proteins containing both SHD1 and SHD2 regardless of the presence of the ZnF are able to associate with the cytoplasmic face of the melanosome membrane (Figure 3 , B, C, L and M). Strom et al., 2002; Wu et al., 2002a; Kuroda et al., 2003; Fukuda and Kuroda, 2004) . Moreover, these studies indicated that two binding sites exist within this region; the first, comprising aa 146-246, interacts with the globular tail of MyoVa and activate its ATPase activity (Fukuda and Kuroda, 2004; Li et al., 2005) , while the second, comprising aa 300-400, mediates interaction with the melanocyte-specific exon F of MyoVa Wu et al., 2002a; Li et al., 2005) . Hereafter, these subdomains will be referred to as GTBD (for globular tail binding domain) and EFBD (for exon 
Identification of a region within the C-terminus ABD of Mlph important for recruitment of
MyoVa to melanosomes
Having confirmed the importance of the MyoVa EFBD of Mlph in recruitment of MyoVa, we then used the melan-ln cells to test the prediction of in vitro data that constructs encoding the R27BD and MBD of Mlph (i.e. aa 1-400) but lacking the ABD (aa 400-590) represent the minimal fragment required for Rab27a-Mlph-MyoVa complex formation and peripheral capture of melanosomes Nagashima et al., 2002; Strom et al., 2002; Wu et al., 2002a) . To do this, we transiently over-expressed Mlph molecules truncated at the C-terminus in melan-ln and performed experiments as above. As expected from in vitro binding studies we found that, in contrast to wild-type Mlph ( In addition, we noticed that Mlph1-483 is able to rescue melanosome transport defects of melan-ln cells with similar efficiency to full length Mlph1-590 (compare Figure 5 , A-D with Q-T and Figure 8B ). This observation indicates that the integrity of parts of Mlph involved in interaction with actin (400-590aa) and microtubule-associated protein EB1 (490-590aa) are not essential for Mlph function as assayed using this method. In order to further test the functional importance of the interaction of Mlph with actin, we used the MlphKA mutant in which a cluster of conserved basic amino acids (K493, R495, R496 and K497 in mouse) that is reported to provide a binding site for actin are converted to alanines (Kuroda et al., 2003) .
Consistent with the idea that the interaction of actin with Mlph is not absolutely critical for
Mlph function, we observed that MlphKA is able to overcome melan-ln melanosome transport defects with similar efficiency to wild-type Mlph ( Figure 5 , U-X, Figure 8B and summarised in Figure 1) .
The potential of Mlph region 440-483aa to form coiled coil structure is essential for melanosomal recruitment of MyoVa.
The three-dimensional structure of Mlph has yet to be solved, however structure prediction software (such as the COILS and Multicoils coiled-coil prediction algorithm) predicts that the aa 440-483 region of Mlph contains an amphipathic α-helix that may associate with other similar α-helices to form a coiled-coil structure (Lupas et al., 1991; Lupas, 1997; Wolf et al., 1997 ) ( Figure 6A ). We hypothesised that formation of a coiled-coil structure in region 440-483 is important for Mlph function and decided to test this prediction using point mutations that specifically disrupt this structure within the context of the full length protein. As with other coiled-coils, aa 440-483 region contains a heptad repeat pattern of amino acids with those at the a and d positions possessing hydrophobic side chains while amino acids at positions e and g possessing charged side chains (Mason and Arndt, 2004) . To specifically disrupt this potential structural motif, the T residue at position 460 (corresponding to the d position of the heptad repeat) was replaced by P, predicted to greatly reduce the probability of coiled-coil structure in this region as determined using the Multicoils algorithm ( Figure   6A ). Over-expression of Mlph T460P results in a protein of the predicted size (unpublished observations) which is able to associate with melanosomes but is unable to promote the stable association of MyoVa with melanosomes ( Figure 6 , B-E). Similar point mutations with respect to the periodicity of the coiled-coil heptad repeat, Mlph M453P (and Mlph A467P , unpublished observations), yielded similar results, i.e., melanosome-associated Mlph proteins that are unable to recruit MyoVa to melanosomes ( Figure 6 , A and F-I). These results are entirely consistent with structure predictions. Interestingly, Mlph M453P is predicted to result in a protein with a shorter coiled-coil structure (aa 454-483) ( Figure 6A ). The latter observation suggests that the size of the potential coiled-coil structure is important.
We extended these observations by testing other Mlph mutants in which T460 is replaced with amino acids other than P, which affect to varying extent the potential for Mlph 440-483 to form coiled coil structure. Whilst P is likely to introduce a kink into the peptide backbone of the mutant Mlph and thus may have long range effects on the structure, other changes might have a more specific effect of disrupting locally the coiled-coil ( Figure 6A ). We observed that there is an inverse correlation between melanosomal recruitment of MyoVa by these Mlph mutants and their potential to disrupt the potential coiled-coil structure ( Figure 6 , A and J-Q).
Sequence comparison indicates that this region of Mlph shares high similarity at the amino acid level with the corresponding region of MyRIP, which is also predicted to form coiledcoil structure by the Multicoils algorithm (unpublished observation; aa724-765 in rat sequence; Figure 6A ). This led us to test the possibility that this part of both proteins allows a conserved function or interaction, as MyRIP is able to bind MyoVa . We thus constructed and expressed a chimeric protein (MlphCC) in which aa 433-511
of Mlph are replaced with aa 699-782 of MyRIP (rat) in melan-ln melanocytes. As expected, this protein is localised to melanosomes and is able to promote association of MyoVa with the cytoplasmic face of melanosome membranes ( Figure 6 , R-U and summarised in Figure   1 ). Together these data provide strong evidence that the capacity of region 440-483 to form coiled coil structure contributes to melanosomal recruitment of MyoVa by both Mlph and MyRIP.
The coiled coil structure of Mlph region 440-483 enhances Mlph MBD interaction with
MyoVa.
As a first step to test the mechanism by which the coiled coil forming Mlph region amino acids 440-483 allows MyoVa recruitment to melanosomes (and rescue of melan-ln melanosome transport defects discussed below), we produced recombinant Mlph and MyoVa proteins and tested their ability to interact in vitro. In order to efficiently express GST-tagged Mlph protein in E.coli, the R27BD was omitted from all proteins as this region contributes significantly to instability of recombinant Mlph (our unpublished observations). Consistent with published data we observed that GST-fusion proteins containing the GTBD (aa 150-266) and MBD (aa150-400), but not GST alone or the coiled-coil region alone (Mlph aa 400-500) are able to interact with the cargo-binding tail of MyoVa aa1258-1853 containing the melanocyte-specific exons D and F (hereafter referred to as MSGTA) ( Figure 7A , lanes 1, 2, 3 and 7; Figure 7B lane 1 ) Nagashima et al., 2002; Strom et al., 2002; Wu et al., 2002a) . Nevertheless, a GST-fusion protein containing the MBD together with the coiled coil region (Mlph150-500) is able to interact significantly more strongly with MSGTA than either of these regions in isolation ( Figure 7A, lane 4) . Furthermore, the enhancement of interaction is ablated by the introduction of point mutation A467P (Mlph150-500AP) predicted to disrupt the coiled-coil structure of this region ( Figure 7A , lane 5). These data are consistent with results observed in living cells and suggest that the coiled-coil region enhances the ability of Mlph MBD to interact with MyoVa.
However, in contrast to the results obtained from the melanosome transport assay that suggest that the GTBD fulfils a non-essential function (Figure 4) , we observed that a fusion protein containing EFBD and coiled coil regions (Mlph300-500, Figure 7A , lane 6) interacts with MSGTA to a lower extent than Mlph150-500 indicating that the GTBD contributes significantly to the ability of Mlph150-500 to interact with MSGTA. One explanation for this discrepancy between in vitro and cell culture results is that the extreme C-terminus, present in MlphΔGTBD, may compensate for the loss of GTBD in allowing sufficient MyoVa to bind to Mlph to allow rescue of melanosome transport. Accordingly, we found that Mlph300-590 is able to associate with MSGTA with efficiency similar to that of Mlph150-500, while a fusion protein containing the MBD, coiled coil and extreme C-terminus region (Mlph150-590) is able to interaction with MSGTA with significantly higher affinity than Mlph150-500 or any of the other truncated proteins ( Figure 7B , lanes 3, 4, and 5). Once more results using an equivalent fusion protein in which A467 is replaced by P (Mlph150-590AP) confirm the important contribution to this interaction that is played by the coiled coil ( Figure 7B , lane 6).
This mutant reduces the level of MyoVa interaction to a level below that achieved by proteins such as Mlph300-590 and Mlph150-500 that correspond to rescuing proteins in the melanosome transport assay (Mlph1-483 and MlphΔGTBD, respectively).
These observations suggest that the Mlph EFBD and coiled-coil must be present in combination with either the GTBD or the extreme C terminus in order to allow sufficient MyoVa interaction to promote rescue of melan-ln melanosome transport defects. To further test this hypothesis in the melanosome transport assay, we expressed Mlph lacking both GTBD and the extreme C terminus (Mlph1-483ΔGTBD) in melan-ln melanocytes.
Consistent with in vitro data, we found that this protein is unable to promote rescue of melanosome transport ( Figure 8B ).
As a second approach to examine the role of the coiled coil and extreme C terminus of Mlph in MyoVa binding, we investigated the interaction of C-terminal truncated Mlph proteins with full length, native MyoVa protein in melanocytes using an adenovirus expression system that allows efficient expression of Mlph in almost 100% of infected melan-ln cells ( Figure 7C ). We then immunoprecipitated Mlph (V5 tagged) and measured the amount of MyoVa associated with the over-expressed protein. Using this approach, we found that Mlph truncated at amino acid 266 or 400 are unable to interact stably with MyoVa ( Figure 7C , lanes 1 and 2). Furthermore, we observed that the wild-type protein is able to recruit MyoVa with significantly greater efficiency (4-5 fold higher) than Mlph truncated at amino acid 490
( Figure 7C, lanes 3 and 4) , as predicted from the experiments described above.
Altogether these biochemical data suggest that truncated Mlph proteins do not interact with MyoVa with the same efficiency as wild-type, however, those containing the two essential domains, EFBD and coiled coil, together with either of the other regions, GTBD and extreme C terminus, allow sufficient levels of MyoVa bind to allow functional rescue.
Melanosomal recruitment of MyoVa by Mlph is essential for peripheral tethering of melanosomes in melanocytes.
Another important question that may be addressed using the melan-ln melanosome transport assay is the relationship between recruitment of MyoVa to melanosomes, activation of the MyoVa and the retention of melanosomes within the peripheral actin cytoskeleton. In order to answer this question, the efficiency of rescue of melan-ln melanosome transport defects was determined for cells over-expressing different Mlph constructs by measuring the proportion of melan-ln cytoplasm that contains melanosomes. Over-expression of wild-type
Mlph resulted in rescue of melanosome transport defects, such that greater than 60% of the cytoplasmic area of melan-ln cells was filled with melanosomes while over-expression of Slp1, here used as negative control, did not increase the proportion of melan-ln cytoplasm occupied by melanosomes above that of non-transfected cells (~30%; Figure 8A 
DISCUSSION
In this study we used a cell culture melanosome transport assay to define critical functional domains of the Mlph protein. In contrast to previous studies in which over-expression of Mlph mutants was observed in wild-type melanocytes, our approach of using Mlph-null cells provides clearer information regarding the formation of the tripartite Rab27a:Mlph:MyoVa complex and in particular the contribution of Mlph domains to melanosome transport as the interpretation of results is not complicated by the presence of wild-type Mlph (Kuroda and Fukuda 2003) . This system also allows the contribution of individual Mlph interacting proteins to be examined by using mutant Mlph proteins that specifically disrupt each protein:protein interaction and then assaying their function in a cellular environment.
Using the cell culture melanosome transport assay we reached several unexpected conclusions regarding Mlph domains and interacting partners. Our data indicate that MyoVa recruitment to melanosomes and recovery of leaden melanosome transport defects cannot be uncoupled. Moreover, we find that a coiled-coil forming region of the Mlph C-terminus tail Leading from this, our second conclusion is that the integrity of the C terminus ABD of Mlph and its ability to associate with actin, EB1 (and MyoVa, this study) appear to be dispensable for melanosome transport in melanocytes. Previously, Mlph aa490-590 was suggested to form a binding site for EB1, while basic amino acids K493, R495, R496 and K497 allow interaction with filamentous actin (Fukuda 2002; Wu et al 2005) . It is suggested that Mlph interaction with actin might enhance the processivity of the MyoVa motor activity while EB1
is proposed to allow transport of Mlph to the periphery of melanocyte cytoplasm prior to Rab27a-Mlph-MyoVa complex formation, via transport at the + tips of growing microtubules. Our data argue that these interactions are likely to fulfil an ancillary function in melanosome transport as rescue of leaden melanosome transport defects occurs with similar efficiency to wild-type when Mlph1-483 or MlphKA are expressed ( Figure 5 and 8) .
Alternatively, these interactions may play an important role in aspects of melanosome transport and pigmentation in vivo that may not be measured using this cell culture assay.
A third unexpected conclusion of our study is that the region of the MBD proposed to be important for interaction with the MyoVa globular tail (GTBD aa150-266) makes a nonessential contribution to Mlph function. Evidence for this is that deletion of this region of Mlph does not affect the ability of the MlphΔGTBD mutant to rescue melanosome transport defects (Figure 4 and 8) . However, these non-essential pieces of Mlph, GTBD and Mlph aa490-590, appear to fulfil a role in stabilisation of the core MyoVa binding region (300-484aa) as their presence enhances the level of MyoVa recruited to melanosome and the presence of either of these pieces is essential for functional rescue of melanosome transport (Figures 4, 5, 7 and 8) .
In addition to these unexpected conclusions, our assay allowed us to confirm the role of other parts of Mlph predicted by earlier studies and to confirm the significance of the contribution that these parts play in Mlph function. First, we confirm that the R27BD allows association with Rab27a-GTP on melanosomes (Figure 3 ). Specifically we show that SHD1 and SHD2
form a minimal R27BD while the ZnF is dispensable for this interaction. This is consistent with the fact that all Rab27 binding Slp and Slac2 family proteins contain SHD1 and SHD2
but not ZnF and suggests that the in situ requirements for interaction of Rab27a and Mlph are more stringent than those reported using recombinant proteins . Second, our results underline the importance of the EFBD of Mlph as mutants MlphΔEFBD and
MlphEA are unable to restore wild-type melanosome transport to leaden melanocytes ( Figure   4 and 8). Thirdly, our biochemical data suggest that truncated Mlph proteins do not interact with MyoVa with the same efficiency as wild-type, however, those containing the two essential domains, EFBD and coiled coil, together with either of the other regions, GTBD and extreme C terminus, allow sufficient levels of MyoVa bind to allow functional rescue.
This raises the possibility that there is some level of functional redundancy between the latter domains. In addition, it is possible that association of MlphMBD with MyoVa may reveal MyoVa binding site(s) within the coiled coil and extreme C terminus of Mlph as these regions alone (Mlph400-500 and Mlph400-590) are unable undertake interaction with MyoVa when isolated from MBD ( Figure 7A ; our unpublished observations).
Finally our study addressed the relationship between recruitment of melanosomal MyoVa and recovery of melan-ln melanosome transport defects. Our finding shows conclusively that
Mlph constructs that are able to recruit MyoVa (~20-40% of wild-type levels) to melanosomes also allowed melanosomes to be retained in peripheral dendrites. Melanosome transport and in vitro binding assays confirm that both EFBD and coiled coil regions together with either GTBD or the extreme C terminus allow this to be achieved ( Figure 4 , 5 and 7).
This striking correlation between MyoVa recruitment and melanosome transport rescue suggests that the critical event in peripheral melanosome transport is the formation of the tripartite complex. One possibility to explain our findings is that melanosomal recruitment is somehow coupled with a conformational change in MyoVa, as has been recently proposed for its functional activation in high Ca ++ (Krementsov et al., 2004; Li et al., 2004; Wang et al., 2004) . Unfortunately, the activation status of MyoVa cannot be probed directly using this assay and future studies should address this possibility using assays that measure the motor activity of MyoVa in vitro.
In conclusion, our data clearly implicate the coiled-coil region of Mlph in MyoVa binding and activation. The structural and functional conservation of this motif in MyRIP opens the possibility that a conserved mechanism for activation of MyoVa and MyoVIIa may exist.
Future studies should be directed towards understanding the structural mechanism by which this is achieved. 
